Document is current
Any future updates will be listed below
-
Authors
Luther, Tomas
Eckerbom, Per
Cox, Eleanor
Lipcsey, Miklos
Bülow, Sara
Hultström, Michael
Torrente, Francisco Martinez
Weis, Jan
Palm, Fredrik
Francis, Susan
Frithiof, Robert
Liss, Per
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02765191 at ClinicalTrials.govDocuments that mention this clinical trial
Decreased renal perfusion during acute kidney injury in critical COVID-19 assessed by magnetic resonance imaging: a prospective case control study
https://doi.org/10.1186/s13054-022-04132-8
-
Funding
Funding for this research was provided by:
NoRCORP
Uppsala Universitet
SciLifeLab/Knut and Alice Wallenberg national COVID-19 research program (KAW 2020.0182, KAW 2020.0241)
Swedish Heart-Lung Foundation (20210089, 20190639, 2019063)
Swedish Society of Medicine (SLS-938101)
Region Uppsala
Medical Research Council (MR/V037005/1)
Swedish Research Council (2014-02569 and 2014-07606)
Swedish Kidney Foundation (F2020-0054)
Ernfors Family Foundation
Selanders Foundation
Uppsala University
- License Information
-
More Information
Article History
Received: 5 May 2022
Accepted: 19 August 2022
First Online: 1 September 2022
Declarations
:
: The study was approved by the Uppsala Regional Ethical Review Agency (No. 2014/381 with amendment No. 2020–01996 and No. 2021–04798). Informed consent was obtained from each patient, or next of kin if the patient was unable to give consent. The Declaration of Helsinki and its subsequent revisions were followed. This is a prospective case control sub-study of the MR-Evaluation of Renal Function In Septic Patients (MERSEP) study, the protocol of the study was pre-registered (ClinicalTrials ID: NCT02765191), first registered May 6 2014 with a COVID-19 updated protocol registered May 7 2020 before first patient was enrolled.
: Institutional funding is accounted for separately. MH and FP are active in the American Physiological Society. The authors declare that they have no relevant competing interests.
